Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 180
Summary
- Conditions
- Rhinitis
- Rhinoconjunctivitis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Screening
Participation Requirements
- Age
- Between 12 years and 65 years
- Gender
- Both males and females
Description
Double blind placebo-controlled study. The subjects will receive medication during 4 months.
Double blind placebo-controlled study. The subjects will receive medication during 4 months.
Tracking Information
- NCT #
- NCT02661854
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Mª Dolores Hernández, PhD; MD Principal Investigator: Pilar Alba, PhD; MD Principal Investigator: Carmen Pérez, PhD; MD Principal Investigator: Javier Montoro, PhD; MD Principal Investigator: Antonio de Mateo, PhD; MD Principal Investigator: David El-Qutob, PhD; MD Principal Investigator: Javier Fernández, PhD; MD Principal Investigator: Vicente Jover, PhD; MD Principal Investigator: Isabel Flores, PhD; MD Principal Investigator: Mónica Antón, PhD; MD Principal Investigator: Carmen Andreu, PhD; MD Principal Investigator: Luis Angel Navarro, PhD; MD Principal Investigator: Ángel Ferrer Study Director: Antonio Nieto, PhD; MD
Get Well Soon